Core Viewpoint - Xuantai Pharmaceutical (688247.SH) expects a significant decline in net profit for the year 2025, with projections indicating a decrease of 57.65% to 64.71% compared to the previous year [1] Financial Performance - The company anticipates a net profit attributable to shareholders of the parent company ranging from 45.07 million to 54.08 million yuan for 2025 [1] - The expected net profit, excluding non-recurring gains and losses, is projected to be between 29.61 million and 35.53 million yuan, reflecting a year-on-year decline of 68.82% to 74.02% [1] Reasons for Decline - The decline in net profit is primarily attributed to: 1. The ongoing implementation of domestic drug procurement policies, which has led to significant price reductions for some products and a narrowing of profit margins [1] 2. Increased competition in overseas markets and adjustments in tariff policies, resulting in a year-on-year decrease in sales and profitability of related products [1] 3. The company has prudently recognized impairment losses on accounts receivable, inventory, goodwill, etc., in accordance with relevant accounting standards, negatively impacting current net profit [1]

格隆汇1月29日丨宣泰医药(688247.SH)公布，经财务部门初步测算，预计2025年年度实现归属于母公司 所有者的净利润4,507.00万元至5,408.00万元，同比下降57.65%至64.71%。预计2025年年度归属于母公 司所有者的扣除非经常性损益的净利润为2,961.00万元至3,553.00万元，同比下降68.82%至74.02%。 报告期内，公司归属于母公司所有者的净利润和归属于母公司所有者的扣除非经常性损益的净利润出现 下滑，主要基于以下原因：1、随着国内药品集采政策持续推进，公司部分产品价格下降明显，利润空 间收窄。在海外市场，部分产品面临行业竞争加剧以及关税政策调整等因素，导致公司相关产品在海外 市场的销售额与盈利水平同比下滑。2、公司基于谨慎性原则，按照《企业会计准则》的相关规定，对 相关的应收账款、存货、商誉等计提了减值损失，对当期净利润产生了负面影响。 ...

每经AI快讯，宣泰医药(688247)1月29日发布2025年业绩预告，预计2025年度公司实现归母净利润4507 万元至5408万元，同比下降57.65%至64.71%。报告期内，随着国内药品集采政策持续推进，公司部分 产品价格下降明显，利润空间收窄。在海外市场，部分产品面临行业竞争加剧以及关税政策调整等因 素，导致公司相关产品在海外市场的销售额与盈利水平同比下滑。 （文章来源：每日经济新闻） ...

每经AI快讯，宣泰医药1月29日晚间发布公告称，2025年度，公司合并报表口径计提各项减值准备共计 1899.22万元，减少公司合并报表利润总额1899.22万元。 （记者 曾健辉） 每经头条（nbdtoutiao）——水贝黄金平台"杰我睿"兑付危机调查：40倍杠杆对赌，金价越涨平台越 亏！老板自称"还在深圳"，投资者：兑付方案本金打两折，无法接受 ...

| | 项目 | 年 2025 1-12 （损失以"-"号填列） | 月计提金额 | | --- | --- | --- | --- | | 信用减值损失 | 应收账款坏账损失 | | -141.06 | | | 其他应收款坏账损失 | | -4.24 | | | 小计 | | -145.30 | | 资产减值损失 | 存货跌价损失 | | -1,543.78 | | | 商誉减值损失 | | -216.46 | | | 合同资产减值损失 | | 6.32 | | | 小计 | | -1,753.92 | | | 合计 | | -1,899.22 | 注：本次计提减值准备计入的报告期间为 2025 年 01 月 01 日至 2025 年 12 月 31 日。 证券代码：688247 证券简称：宣泰医药 公告编号：2026-005 上海宣泰医药科技股份有限公司 关于 2025 年度计提资产减值准备的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、计提减值准备情况概述 根据《企业会计准则》《上海证券交易所科创板股票上 ...

Core Viewpoint - The company expects a significant decline in net profit and revenue for the fiscal year 2025 compared to the previous year, primarily due to price reductions in domestic drug procurement policies and increased competition in overseas markets [1] Financial Performance - The company anticipates a net profit attributable to shareholders of the parent company between 45.07 million and 54.08 million yuan for 2025, representing a decrease of 73.62 million to 82.63 million yuan year-on-year, which corresponds to a decline of 57.65% to 64.71% [1] - The expected operating revenue for 2025 is projected to be between 394 million and 473 million yuan, reflecting a decrease of 39.02 million to 118 million yuan compared to the previous year, equating to a decline of 7.63% to 23.02% [1] Reasons for Decline - The decline in net profit and revenue is attributed to several factors: 1. The ongoing domestic drug procurement policy has led to significant price reductions for some products, narrowing profit margins 2. Increased competition and adjustments in tariff policies in overseas markets have resulted in decreased sales and profitability for related products [1] - The company has also made provisions for impairment losses on accounts receivable, inventory, and goodwill based on prudence principles according to relevant accounting standards, negatively impacting current net profit [1]

宣泰医药公告称，预计2025年年度营收39383.00万元至47260.00万元，同比降7.63%至23.02%；归母净 利润4507.00万元至5408.00万元，同比降57.65%至64.71%；扣非归母净利润2961.00万元至3553.00万 元，同比降68.82%至74.02%。业绩下滑主因国内药品集采使部分产品价格下降、海外市场竞争加剧及 关税政策调整，且公司计提减值损失。数据未经审计，准确财务数据以年报为准。 ...

证券代码：688247 证券简称：宣泰医药 公告编号：2026-006 上海宣泰医药科技股份有限公司 2025 年年度业绩预告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、本期业绩预告情况 （一）业绩预告期间 2025 年 1 月 1 日至 2025 年 12 月 31 日。 （二）业绩预告情况 （1）经财务部门初步测算，预计 2025 年年度实现营业收入 39,383.00 万元 至 47,260.00 万元，与上年同期相比，将减少 3,901.93 万元至 11,778.93 万元，同 比下降 7.63%至 23.02%。 （2）预计 2025 年年度实现归属于母公司所有者的净利润 4,507.00 万元至 5,408.00 万元，与上年同期相比，将减少 7,362.06 万元至 8,263.06 万元，同比下 降 57.65%至 64.71%。 （3）预计 2025 年年度归属于母公司所有者的扣除非经常性损益的净利润为 2,961.00 万元至 3,553.00 万元，与上年同期相比，将减少 7,843.60 ...

1月26日，宣泰医药涨0.94%，成交额6619.64万元。两融数据显示，当日宣泰医药获融资买入额928.16 万元，融资偿还961.93万元，融资净买入-33.77万元。截至1月26日，宣泰医药融资融券余额合计 9952.79万元。 融资方面，宣泰医药当日融资买入928.16万元。当前融资余额9930.71万元，占流通市值的2.03%，融资 余额超过近一年60%分位水平，处于较高位。 融券方面，宣泰医药1月26日融券偿还200.00股，融券卖出0.00股，按当日收盘价计算，卖出金额0.00 元；融券余量2.05万股，融券余额22.08万元，超过近一年90%分位水平，处于高位。 资料显示，上海宣泰医药科技股份有限公司位于上海市浦东新区海科路99号3号楼一楼，成立日期2012 年8月13日，上市日期2022年8月25日，公司主营业务涉及仿制药的研发、生产和销售以及CRO服务。 主营业务收入构成为：产品销售收入69.85%，CRO研发服务9.38%，权益分成收入6.50%，CMO加工服 务6.31%，代理权收入3.93%，自研项目转让收入3.89%，其他(补充)0.12%。 机构持仓方面，截止2025年9月30日 ...

Core Viewpoint - The company focuses on high-end generic drugs and integrated CRO/CMO services, while accelerating the development of modified new drugs [1] Group 1: High-End Generic Drugs - The company is deeply engaged in the high-end generic drug sector [1] - It aims to transition from a generic drug company to a hybrid specialty pharmaceutical company [1] Group 2: Innovative Drug Development - The first self-developed modified new drug project, XT-0043, has shown excellent safety and efficacy in Phase II clinical trials and has successfully reached clinical endpoints [1] - The company is fully advancing the initiation and implementation of Phase III clinical trials based on Phase II clinical data [1] Group 3: Injection Drug Development - The company is actively enhancing its research and development capabilities in the injection drug field [1] - It is accelerating the construction of complex injection drug formulation technology platforms, including lyophilized injections, liposomes, and long-acting injections [1]